Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06615050 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 33 wordsv24 See this version in full on ClinicalTrials.gov ↗
  2. Study sites: 28 to 30v23
  3. Study sites: 27 to 28v22
  4. Study sites: 26 to 27v21
  5. Study sites: 25 to 26v20
Show 18 earlier versionsHide 18 earlier versions
  1. Study sites: 23 to 25v19
  2. Study sites: 21 to 23v18
  3. Study sites: 20 to 21v17
  4. Study sites: 19 to 20v16
  5. Study sites: 18 to 19v15
  6. Study sites: 15 to 18v14
  7. Study sites: 14 to 15v13
  8. Study sites: 11 to 14v12
  9. Study sites: 7 to 11v11
  10. Study sites: 5 to 7v10
  11. Study sites: 4 to 5v9
  12. Study sites: 3 to 4v8
  13. Start date changed from estimate of Apr 7, 2025 to Apr 2, 2025v7
  14. Study sites: 1 to 3 Start date: Mar 17, 2025 to Apr 7, 2025v6 Show 1 more changeShow less
    • Start date: Mar 17, 2025 to Apr 7, 2025
  15. Trial status: Not Yet Recruiting to Recruiting Start date: Feb 3, 2025 to Mar 17, 2025 · Study sites: 0 to 1 · Primary and study completion dates: Oct 20, 2030 to Jan 17, 2031v5 Show 3 more changesShow less
    • Start date: Feb 3, 2025 to Mar 17, 2025
    • Study sites: 0 to 1
    • Primary and study completion dates: Oct 20, 2030 to Jan 17, 2031
  16. Start date: Dec 9, 2024 to Feb 3, 2025v4
  17. Study Status, Referencesv3
  18. Study title expanded, about 3 wordsv2 See this version in full on ClinicalTrials.gov ↗
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Incyte
94 trials monitored
See 9 trials at risk
The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation
Trial Details
NCT Number NCT06615050
Lead Sponsor Incyte Corporation
Collaborators: Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI)
Conditions Graft-versus-host Disease (GVHD)
Enrollment 572 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov